SCHEMBL647724

SCHEMBL647724

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1)Cc1cc(C)c(OC)c(C)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.44
TSHR P16473 4/20 0.40
CRHR1 P34998 2/20 0.36
MAPK1 P28482 1/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
HSD17B10 Q99714 2/20 0.35
TP53 P04637 1/20 0.35
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PDE4B Q07343 2/20 0.35
NR1H3 Q13133 1/20 0.34
CNR2 P34972 2/20 0.34
CNR1 P21554 1/20 0.34
CASR P41180 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650206 0.94 C5AR1 (0.43) C5AR1TSHRMAPK1KDM4EALDH1A1
SCHEMBL650679 0.93 C5AR1 (0.43) C5AR1TSHRCRHR1KDM4EALDH1A1
SCHEMBL648986 0.90 C5AR1 (0.42) C5AR1TSHRCRHR1MAPK1KDM4E
SCHEMBL648946 0.90 C5AR1 (0.41) C5AR1TSHRCRHR1MEN1KMT2A
SCHEMBL652063 0.90 C5AR1 (0.40) C5AR1TSHRKDM4EALDH1A1HSD17B10
SCHEMBL650460 0.90 C5AR1 (0.40) C5AR1TSHRCRHR1KDM4EALDH1A1
SCHEMBL1912975 0.89 TSHR (0.49) C5AR1TSHRCRHR1MAPK1KDM4E
SCHEMBL650339 0.89 C5AR1 (0.41) C5AR1TSHRCRHR1KDM4EALDH1A1
SCHEMBL650192 0.89 CRHR1 (0.45) C5AR1TSHRCRHR1MAPK1
SCHEMBL651094 0.89 TSHR (0.50) C5AR1TSHRMAPK1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed